|
Serbia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Serbia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Serbia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Serbian pharmaceutical and healthcare industry.
Competitive intelligence, Serbian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Serbian market.
The Serbia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Serbia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Serbian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Serbia to test other views – a key input for successful budgeting and strategic business planning in the Serbian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Serbian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Serbia.
- Exploit The Latest Competitive Serbian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Serbia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Serbia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Serbia Pharmaceuticals And Healthcare Industry SWOT |
| Serbia Political SWOT |
| Serbia Economic SWOT |
| Serbia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
Chapter - Serbia - Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| IP Disputes |
| Pricing Regime |
| Reimbursement Regime |
| Table Serbia - Examples of Reimbursed Medicines by Category |
| Price Cuts |
| Price Rises |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Table: Top 10 Causes Of Death In Serbia And Montenegro |
| Healthcare Sector |
| Table Serbia – Major General And Specialised Hospitals |
| Healthcare Insurance |
| Healthcare Reform |
| Medical Tourism |
| Table: Cosmetic Surgery Costs |
| Pharmaceutical Sector |
| Domestic Pharmaceutical Industry |
| Domestic Company Activity |
| Foreign Pharmaceutical Industry |
| Foreign Company Activity |
| Table: Proposed Members Of Serbia's Pharmaceutical Industry Association |
| Stada Sales vs Generic Market Growth |
| Pharmaceutical Wholesale And Retail |
| Clinical Trials |
| Table: Number Of Ongoing Clinical Trials In Serbia |
| Medical Devices |
| Medical Device Classification In Serbia |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Serbia -–Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Serbia – Health Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Serbia - Economic Activity |
Chapter - Prescription Market Forecast |
| Table: Serbia – Prescription Market Indicators, Historical Data And Forecasts (RSDmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Serbia – Patented Market Indicators, Historical Data And Forecasts |
| Generics Market Forecast |
| Table: Serbia – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table Serbia – Sales Of Herbal Remedies 2007 |
| Table Serbia – Sales Of Homeopathic Remedies 2007 |
| Table: Serbia – OTC Market Indicators, Historical Data And Forecasts (RSDmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Serbia – Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Medical Devices Forecasts |
| Table: Serbia - Medical Device Market, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Serbia – Other Healthcare Indicators, Historical Data And Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Companies Involved In The Serbian Pharmaceutical Industry |
| Table: Serbia – Pharmaceutical Product Sales By Therapeutic Category (2007) |
| Table Serbia – Defined Daily Dose (DDD) Per 1,000 Inhabitants |
Chapter - Company Monitor |
| Multinational Company Profiles |
| Pfizer |
| GlaxoSmithKline |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Indigenous Company Profiles |
| Hemofarm (Stada) |
| Galenika |
| Zdravlje Actavis |
| Jugoremedija |
Chapter - Country Snapshot: Serbia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000/01 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Serbia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI Business Environment Rating matrix for Q209, Serbia is found in a much improved 14th position, out of the 20 key markets surveyed in the Central and Eastern Europe (CEE) region. The value of the Serbian pharmaceutical market was estimated at US$1.17bn in 2008, with the figure likely to top US$1.52bn by the end of 2013, increasing by a compound annual growth rate (CAGR) of 8.36% in local currency terms. Generics represent almost a third of the market by value, with their further development to be stimulated by low incomes, strong domestic industry, and the lack of state financing for widerranging reimbursement coverage. While small by global standards, the key draws of the Serbian market include its advantageous geographical position, a largely untapped pharmaceutical market, and the low cost of skilled labour. The recent Good Manufacturing Practice (GMP) accredition of Zdravlje Actavis’ local production facilities, as well as Hemofarm’s new status as the first Serbian company to export medicines to the US, illustrates the pace of the market development. However, Serbia will continue to be a challenging market for foreign investors because of the prevalence of corruption, a large-scale blackmarket economy, and the poor state of the country's infrastructure.
Nevertheless, Serbia has actively been creating a business-friendly environment and a modern market economy, which has led to a spate of foreign direct investment (FDI) in the country’s pharmaceutical industry. An 80% stake in Galenika and a 70% stake in the Mataruska and Bogutovacka spa resorts is presently up for sale. The government has passed several important laws aimed at developing a more favourable environment for foreign investments, and at harmonising Serbian legislation with that of the European Union (EU) and its economic policies. Core measures include legislation regulating companies, bankruptcy procedures, financial markets, securities, and transfer of capital. The tax regime for foreign investors is an additional stimulus. While net FDI inflows are relatively low in comparison to the rest of the region, we anticipate that these will pick up as: the government commits to stimulating foreign investments; further adherence towards EU norms occurs; and the privatisation process picks up speed.
In the meantime, despite the positive developments just mentioned, Serbian pharmaceutical manufacturers are facing challenging times, as indicated by depreciation of local tender and an 8.9% contraction in the country’s industrial output (recorded in December 2008 by the National Statistics Office). The ‘manufacturing’ component of output, which comprises some 75.8% of the total, fell by 9.4% year-on-year (y-o-y). We are projecting it to average -6% in 2009, based on our negative outlook for Serbia's key trade partners, namely the eurozone and the members of the Central European Free Trade Agreement (CEFTA) – which accounted for 33% of total Serbian exports in January-November 2008. Lastly, falling soft commodity and energy prices globally will also have a negative impact on both Serbian industrial production volumes and indices over the forecast period, with BMI forecasting a 3.4% GDP growth in 2009, down from the 6.3% predicted previously.
|
Serbia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |